Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease Emphysema Age 40 or older 2. Diagnosis of severe COPD 3. Stopped smoking for at least 6 months prior to entering the study. 4. Completed a pulmonary rehabilitation program within 12 months prior to treatment and/or regularly performing maintenance respiratory rehabilitation if initial supervised therapy occurred more than 12 months prior to baseline testing. 5. Received Influenza vaccination consistent with local recommendations and/or policy. 6. Read, understood and signed the Informed Consent form. 7. Dyspnea scoring ≥2 on mMRC scale of 0-4. 8. FEV1%pred <45% and FEV1/FVC <60%. 9. TLC%pred >100% AND RV%pred >175%. 10. RV/TLC >55% 11. CT thorax must demonstrate heterogeneous emphysema and a disrupted interlobar fissure (75-90% intact) in the treatment lobe. Scans will be analysed using in-house software to calculate a heterogeneity score and percentage fissure integrity. 12. Chartis balloon catheter assessment confirms the presence of collateral ventilation in the target lobe  Patient unable to provide informed consent. 2. Subject has a history of recurrent clinically significant respiratory infections, defined as 3 or more hospitalizations for respiratory infection during the year prior to enrolment. 3. Subject has clinically significant bronchiectasis. 4. Alpha-1 AT deficiency. 5. Medical history of asthma. 6. Subject has co-morbidities that may significantly reduce ability to improve exercise capacity (e.g., severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnoea. 7. Subject has evidence of other severe disease (such as, but not limited to, lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study. 8. Subject is pregnant or lactating, or plans to become pregnant within the study timeframe. 9. Subject has an inability to tolerate bronchoscopy under conscious sedation or general anaesthesia. 10. Subject has severe gas exchange abnormalities as defined by: PaCO2 >8.0 kPa and/or PaO2 < 6.0 kPa (on room air). 11. FEV1 <15% predicted and Total lung CO uptake (TLCO) <20% predicted. 12. Subject has an inability to walk >140 meters in 6 minutes. 13. Subject has severe pulmonary hypertension defined by right ventricular systolic pressure >45 mm Hg measured on transthoracic echocardiogram. 14. Subject has giant bullae >1/3 lung volume. 15. Lung nodule requiring surgery. 16. Subject has had previous LVR surgery, lung transplantation or lobectomy. 17. Subject has been involved in pulmonary drug or device studies within 30 days prior to this study. 18. Subject is taking >10 mg prednisone (or equivalent dose of a similar steroid) daily. 19. Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder. 20. Subject is on an antiplatelet (such as Plavix) or anticoagulant therapy (such as Warfarin or NOAC) which cannot be stopped prior to the procedure. 21. Subject has a known sensitivity or allergy to Nickel. 22. Subject has a known sensitivity to drugs required to perform bronchoscopy. 23. Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere